BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 57.13 million. The enterprise value is 53.03 million.
| Market Cap | 57.13M |
| Enterprise Value | 53.03M |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 313.76 million shares outstanding. The number of shares has increased by 2.82% in one year.
| Current Share Class | 313.76M |
| Shares Outstanding | 313.76M |
| Shares Change (YoY) | +2.82% |
| Shares Change (QoQ) | +1.91% |
| Owned by Insiders (%) | 6.30% |
| Owned by Institutions (%) | 0.04% |
| Float | 270.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.29 |
| PB Ratio | 17.77 |
| P/TBV Ratio | 8.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.39 |
| EV / Sales | 4.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.14 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 1.19.
| Current Ratio | 1.67 |
| Quick Ratio | 1.54 |
| Debt / Equity | 1.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -35.50 |
Financial Efficiency
Return on equity (ROE) is -277.93% and return on invested capital (ROIC) is -107.90%.
| Return on Equity (ROE) | -277.93% |
| Return on Assets (ROA) | -80.14% |
| Return on Invested Capital (ROIC) | -107.90% |
| Return on Capital Employed (ROCE) | -219.40% |
| Revenue Per Employee | 257,262 |
| Profits Per Employee | -234,310 |
| Employee Count | 44 |
| Asset Turnover | 1.11 |
| Inventory Turnover | 17.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.74% in the last 52 weeks. The beta is -0.24, so BioLargo's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +3.74% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 58.13 |
| Average Volume (20 Days) | 509,495 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, BioLargo had revenue of 10.81 million and -9.84 million in losses. Loss per share was -0.03.
| Revenue | 10.81M |
| Gross Profit | 5.03M |
| Operating Income | -12.46M |
| Pretax Income | -12.78M |
| Net Income | -9.84M |
| EBITDA | -12.31M |
| EBIT | -12.46M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 4.55 million in cash and 3.81 million in debt, giving a net cash position of 736,000 or 0.00 per share.
| Cash & Cash Equivalents | 4.55M |
| Total Debt | 3.81M |
| Net Cash | 736,000 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 3.22M |
| Book Value Per Share | 0.02 |
| Working Capital | 2.32M |
Cash Flow
In the last 12 months, operating cash flow was -8.62 million and capital expenditures -8,000, giving a free cash flow of -8.63 million.
| Operating Cash Flow | -8.62M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -8.63M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 46.53%, with operating and profit margins of -115.32% and -91.08%.
| Gross Margin | 46.53% |
| Operating Margin | -115.32% |
| Pretax Margin | -118.27% |
| Profit Margin | -91.08% |
| EBITDA Margin | -113.91% |
| EBIT Margin | -115.32% |
| FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.82% |
| Shareholder Yield | -2.82% |
| Earnings Yield | -17.23% |
| FCF Yield | -15.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioLargo has an Altman Z-Score of -20.44 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.44 |
| Piotroski F-Score | 2 |